Swan Capital’s AstraZeneca AZN Stock Holding History

Swan Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7	Closed	-$997	–	515
2025 Q3	$997	Buy	+7	New	+$1.06K	﹤0.01%	391
2025 Q1	–	Sell	-19	Closed	-$2.42K	–	388
2024 Q4	$2.42K	Buy	+19	New	+$2.66K	﹤0.01%	222

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Swan Capital's AZN Position: Q4 2025 in Review

Swan Capital sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 7 shares — an estimated $997 sold.

Swan Capital first reported a position in AZN in Q4 2024 and held it in 2 quarters. The position peaked at $2.42K in Q4 2024. 1,408 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Swan Capital reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
Swan Capital sold 7 AstraZeneca shares in Q4 2025, an estimated $997.
Swan Capital first reported a position in AstraZeneca in Q4 2024 and held it in 2 quarters.
Swan Capital's AstraZeneca position peaked at $2.42K in Q4 2024.
1,408 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Swan Capital's 13F filing for Q4 2025, filed 12 Feb 2026.